Literature DB >> 30108057

Erenumab is effective in reducing migraine frequency and improving physical functioning.

Paolo Martelletti1.   

Abstract

Entities:  

Keywords:  clinical trials; migraine; preventive medicine

Mesh：

Substances：

Year:  2018        PMID： 30108057     DOI： 10.1136/bmjebm-2018-110937

Source DB:  PubMed          Journal:  BMJ Evid Based Med        ISSN： 2515-446X


× No keyword cloud information.
  3 in total

1.  Erenumab in Chronic Migraine Patients Who Previously Failed Five First-Line Oral Prophylactics and OnabotulinumtoxinA: A Dual-Center Retrospective Observational Study.

Authors:  Bianca Raffaelli; Rea Kalantzis; Jasper Mecklenburg; Lucas Hendrik Overeem; Lars Neeb; Astrid Gendolla; Uwe Reuter
Journal:  Front Neurol       Date:  2020-05-28       Impact factor: 4.003

2.  Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy.

Authors:  Raffaele Ornello; Alfonsina Casalena; Ilaria Frattale; Amleto Gabriele; Giannapia Affaitati; Maria Adele Giamberardino; Maurizio Assetta; Maurizio Maddestra; Fabio Marzoli; Stefano Viola; Davide Cerone; Carmine Marini; Francesca Pistoia; Simona Sacco
Journal:  J Headache Pain       Date:  2020-04-07       Impact factor: 7.277

Review 3.  The appropriate dosing of erenumab for migraine prevention after multiple preventive treatment failures: a critical appraisal.

Authors:  Raffaele Ornello; Cindy Tiseo; Ilaria Frattale; Giulia Perrotta; Carmine Marini; Francesca Pistoia; Simona Sacco
Journal:  J Headache Pain       Date:  2019-10-30       Impact factor: 7.277
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.